Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Uptake of CAR T cell therapy in Europe

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Computational Biology Training in Hematology Hall of Fame

Clinical Research Training in Hematology Hall of Fame

Translational Research Training in Hematology Hall of Fame

Hematology 2.0: navigating the world of medical apps

Interview with Dr Alex Langridge, SpR, by Dr Nuno Borges, MBBS, MRes, on behalf of YoungEHA. Despite the controversy surrounding them, medical apps remain extremely popular and lucrative endeavors.